Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Heterocyclic carbon compounds containing a hetero ring...
Reexamination Certificate
2007-12-11
2007-12-11
Padmanabhan, Sreeni (Department: 1617)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Heterocyclic carbon compounds containing a hetero ring...
C424S405000
Reexamination Certificate
active
11533535
ABSTRACT:
The present invention relates to a novel oral pharmaceutical suspension of Cefdinir crystal. More specifically, the present invention relates to a novel kit for preparation of an oral pharmaceutical suspension containing crystal form C Cefdinir.
REFERENCES:
patent: 4409214 (1983-10-01), Takaya et al.
patent: 4559334 (1985-12-01), Takaya et al.
patent: 4935507 (1990-06-01), Takaya et al.
patent: 6350869 (2002-02-01), Sturm et al.
patent: 7022841 (2006-04-01), Cvetovich et al.
patent: 2003/0204082 (2003-10-01), Manca et al.
patent: 2004/0210049 (2004-10-01), Lee et al.
patent: 2004/0242556 (2004-12-01), Dandala et al.
patent: 2004/0242557 (2004-12-01), Dandala et al.
patent: 2005/0059818 (2005-03-01), Duerst et al.
patent: 2005/0080070 (2005-04-01), Deshpande et al.
patent: 2005/0080255 (2005-04-01), Kumar et al.
patent: 2005/0119244 (2005-06-01), Monguzzi et al.
patent: 2005/0131079 (2005-06-01), Pujara
patent: 2005/0137182 (2005-06-01), Dandala et al.
patent: 2005/0209211 (2005-09-01), Law et al.
patent: 2005/0209451 (2005-09-01), Manca et al.
patent: 2005/0215781 (2005-09-01), Chandrasekaran et al.
patent: 2005/0245738 (2005-11-01), Singh et al.
patent: 2006/0025399 (2006-02-01), Law et al.
patent: 2006/0029674 (2006-02-01), Sever et al.
patent: 2006/0040915 (2006-02-01), Kumar et al.
patent: 2006/0069079 (2006-03-01), Sever et al.
patent: 2006/0074236 (2006-04-01), Pozzi et al.
patent: 2006/0094703 (2006-05-01), Deshpande et al.
patent: 2006/0122165 (2006-06-01), Daemon et al.
patent: 2006/0135500 (2006-06-01), Ohnishi et al.
patent: 2006/0135761 (2006-06-01), Datta et al.
patent: 2006/0142261 (2006-06-01), Law et al.
patent: 2006/0142563 (2006-06-01), Law et al.
patent: 2006/0167242 (2006-07-01), Berghausen
patent: 2006/0211676 (2006-09-01), Law et al.
patent: 03 04019 (1989-02-01), None
patent: 304019 (1989-02-01), None
patent: 1609793 (2005-12-01), None
patent: 62-206199 (1987-08-01), None
patent: WO 9724358 (1997-07-01), None
patent: 99/55710 (1999-11-01), None
patent: 02/098884 (2002-12-01), None
patent: WO 03050124 (2003-06-01), None
patent: 2004/016623 (2004-02-01), None
patent: 2004/035800 (2004-04-01), None
patent: 2004/046154 (2004-06-01), None
patent: 2004/058695 (2004-07-01), None
patent: WO 2004056835 (2004-07-01), None
patent: WO 2004085443 (2004-10-01), None
patent: WO 2004104010 (2004-12-01), None
patent: 2005/030178 (2005-04-01), None
patent: 2005/060936 (2005-07-01), None
patent: 2005/090361 (2005-09-01), None
patent: WO 2005090360 (2005-09-01), None
patent: WO 2006010978 (2006-02-01), None
patent: WO 2006018807 (2006-02-01), None
patent: WO 2006035291 (2006-04-01), None
English Translation of JP 63-35961 to Takaya et al.
Davidovich et al, Detection of Polymorphism by Powder X-Ray Diffraction: Interference by Preferred Orientation, 2004, vol. 7, No. 1, pp. 10, 12, 14, 15 and 100.
Joel Bernstein, Polymorphism in Molecular Crystals, 2002, Clarendon Press, pp. 117-118 and 272.
Powers et al, Comparison of the Palatability of the Oral Suspension of Cefdinir vs. Amoxicillin/Clavulanate Potassium, Cefprozil and Azitromycin in Pediatric Patients, 2000, Pediatric Infectious Disease Journal, vol. 19, pp. S174-S180.
Harry G. Britain, Polymorphism in Pharmaceutical Solids, 1999, MArcel Dekker, pp. 184-185 and 236.
U.S. Pharmacopia #23, National Formulary #18, X-Ray Diffraction, 1995, pp. 1843-1844.
Elena Portyansky, Bug Beater: Cephalosporin offers Extended Spectrum of Activity, 1996, Drug Topics, vol. 142, No. 2, pp. 28 and 31.
Inamoto et al, FK 482, A New Orally Active Cephalosporin Synthesis and Biological Properties, 1988, The Journal of Antibiotics, pp. 828-830.
U.S. Food and Drug Administration FDA Aproved Label for Omnicef, label approved on Jul. 14, 1999.
Kazuo Sakane, et al., “Research and Development of New Oral Cephems, Cefixime and Cefdinir”; Fujisawa Pharmaceutical Co., Ltd.; eviews, vol. 113, p. 605-626, 1993.
Yoshihiko Okamoto, et al., “Degradation Kinetics and Isomerization of Cefdinir, a New Oral Cephalosporin, in Aqueous Solution. 1” Journal of Pharmaceutical Sciences, vol. 85, No. 9, Sep. 1996, p. 976-983.
Mino R. Caira, “Crystalline Polymorphism of Organic Compounds”, Topics in Current Chemistry, XP-001156954, vol. 198, 1998, p. 163-208.
Walter Cabri, et al. “Cefdinir: a comparative study of anhydrous vs. monohydrate form” European Journal of Pharmaceutics and Biopharmaceutics, vol. 64, No. 2, 2006, p. 212-221.
Akiko Shimizu Ibuka, et al., “Crystal Structure of Extended-Spectrum b-lactamase Toho-1: Insights into the Molecular Mechanism for Catalytic Reaction and Substrate Specificity Expansion” Biochemistry, vol. 42, No. 36, 2003, p. 10634-10643.
Shehel Deguchi, et al., “Structural studies on copper(II) complex containing (Z)-2-(2-aminothiazol-4-yl)-N-(2-hydroxyethyl)-2-(hydroxyimino)acetamide, a model compound for a cephalosporin antibiotic cefdinir” Journal of Inorganic Biochemistry, vol. 65, No. 3, 1997, p. 191-197.
Shuhei Deguchi, et al., “Structural studies on an iron(II) complex containing (Z)-2-(2-aminothiazol-4-yl)-N-(2-hydroxyethyl)-2-(hydroxyimino)acetamide, a model compound for a cephalosporin antibiotic cefdinir” Journal of the Chemical Society, Dalton Transactions: Inorganic Chemsitry, vol. 9, 1996, p. 1967-1971.
Hisashi Mimura, et al. “Estimation of grinding effect on the solid-state stability of cefdinir by use of microcalorimetry” Drug Stability, vol. 1, No. 1, 1995, p. 34-39.
English Translation of Sakane, K., et al., “Research and Development of New Oral Cephems, Cefixime and Cefdinir”; Fujisawa Pharmaceutical Co., Ltd.; eviews, vol. 113, p. 605-626, 1993.
Deguchi Shuhei
Kitamura Satoshi
Ohnishi Naozumi
Astellas Pharma Inc.
Carter Kendra D.
Oblon & Spivak, McClelland, Maier & Neustadt P.C.
Padmanabhan Sreeni
LandOfFree
Oral pharmaceutical suspension of Cefdinir crystal does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Oral pharmaceutical suspension of Cefdinir crystal, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Oral pharmaceutical suspension of Cefdinir crystal will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3896465